XML 56 R16.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Income Taxes | 12 Months Ended
--- | ---
Dec. 31, 2024
Income Tax Disclosure [Abstract] |
Income Taxes | Income Taxes The following table presents components of loss before income taxes for the periods presented (in thousands):
|  | Year Ended December 31,
|  | 2024 |  | 2023 |  | 2022
United States |  | $ | (22,903) |  |  | $ | (80,348) |  |  | $ | (76,280) |
International |  | 10,148 |  |  | 925 |  |  | (13,982) |
Loss before income taxes |  | $ | (12,755) |  |  | $ | (79,423) |  |  | $ | (90,262) |
Provision for (benefit from) income taxes for the periods presented consisted of (in thousands):
|  | Year Ended December 31,
|  | 2024 |  | 2023 |  | 2022
Current: |  |  |  |  |  |
U.S. federal |  | $ | 519 |  |  | $ | — |  |  | $ | — |
U.S. state |  | 2,728 |  |  | 2,531 |  |  | 576 |
Foreign |  | 1,628 |  |  | (243) |  |  | 724 |
Total provision for income taxes - Current |  | 4,875 |  |  | 2,288 |  |  | 1,300 |
Deferred: |  |  |  |  |  |
U.S. federal |  | (4,308) |  |  | — |  |  | — |
U.S. state |  | (1,174) |  |  | — |  |  | — |
Foreign |  | 647 |  |  | 53 |  |  | 3,088 |
Total (benefit from) provision for income taxes - Deferred |  | (4,835) |  |  | 53 |  |  | 3,088 |
Total provision for income taxes |  | $ | 40 |  |  | $ | 2,341 |  |  | $ | 4,388 |
The Company recorded current income tax expense during 2024 principally due to U.S. taxable income as a result of IRC Section 174 research and experimental capitalization requirements. The Company offset federal taxable income through the utilization of available net operating loss carryforward attributes. However, the Company was subject to net operating loss utilization limitations in some U.S. federal and state jurisdictions. These considerations were partially offset by the Company's acquisition of Acqueon, which carried a U.S. net deferred tax liability balance and provided the Company with a source of taxable income to release a portion of the consolidated U.S. valuation allowance. Income tax expense differed from the amount computed by applying the U.S. federal statutory income tax rate of 21% to pre-tax (loss) income for the periods presented as a result of the following (in thousands):
|  | Year Ended December 31,
|  | 2024 |  | 2023 |  | 2022
U.S. federal tax at statutory rate |  | $ | (2,679) |  |  | $ | (16,676) |  |  | $ | (18,957) |
U.S. state income taxes |  | 1,553 |  |  | 2,531 |  |  | 576 |
Section 162(m) |  | 4,474 |  |  | 6,417 |  |  | 3,851 |
Global intangible low-taxed income |  | — |  |  | (4,002) |  |  | 4,127 |
Effect of waived tax deductions - Base Erosion and Anti-Abuse Tax |  | (7,751) |  |  | 7,751 |  |  | — |
Miscellaneous permanent tax adjustments |  | 26 |  |  | 230 |  |  | 78 |
Research and development credit |  | (1,383) |  |  | (943) |  |  | (1,194) |
Stock-based compensation |  | 16,981 |  |  | 10,829 |  |  | 1,722 |
Transaction costs |  | 862 |  |  | 415 |  |  | — |
Tax benefit from acquisition/reorganizations |  | (4,308) |  |  | — |  |  | (3,852) |
Foreign tax rate differential |  | 525 |  |  | (383) |  |  | 6,749 |
Adjustments related to tax positions taken during prior years |  | (2,083) |  |  | 249 |  |  | — |
Change in valuation allowance |  | (6,177) |  |  | (4,077) |  |  | 11,288 |
Total provision for income taxes |  | $ | 40 |  |  | $ | 2,341 |  |  | $ | 4,388 |
The tax effects of temporary differences that give rise to significant portions of the Company’s deferred tax assets and liabilities as of December 31, 2024 and 2023 related to the following (in thousands):
|  | December 31,
|  | 2024 |  | 2023
Deferred tax assets: |  |  |  |
Net operating loss and credit carryforwards |  | $ | 91,826 |  |  | $ | 115,137 |
Capitalized R&D costs |  | 78,961 |  |  | 55,167 |
Accrued liabilities |  | 872 |  |  | 617 |
Provision for credit losses |  | 671 |  |  | 1,236 |
Property and equipment |  | 35 |  |  | — |
Amortizable intangibles |  | — |  |  | 29 |
Deferred revenue |  | 3,687 |  |  | 2,440 |
Accrued compensation |  | 5,797 |  |  | 4,132 |
Long-term lease liabilities |  | 15,928 |  |  | 11,171 |
Stock-based compensation |  | 10,224 |  |  | 9,190 |
Deferred interest expense |  | 349 |  |  | — |
Other |  | 755 |  |  | — |
Gross deferred tax assets |  | 209,105 |  |  | 199,119 |
Valuation allowance |  | (123,141) |  |  | (134,802) |
Net deferred tax assets |  | 85,964 |  |  | 64,317 |
Deferred tax liabilities: |  |  |  |
Property and equipment |  | (8,647) |  |  | (7,037) |
Amortizable intangibles |  | (7,697) |  |  | — |
Right of use assets |  | (13,493) |  |  | (9,092) |
Deferred contract acquisition costs |  | (52,663) |  |  | (44,217) |
Other |  | — |  |  | (205) |
Gross deferred tax liabilities |  | (82,500) |  |  | (60,551) |
Net deferred taxes |  | $ | 3,464 |  |  | $ | 3,766 |
To enhance clarity, the Company has revised certain disclosures in its effective tax rate reconciliation and disclosure of its deferred tax assets and liabilities, and has conformed prior year disclosures to ensure comparability with the current year. With the exception of Russia, the Company has not provided for U.S. income taxes on undistributed earnings of its foreign subsidiaries because it intends to permanently re-invest those earnings outside the United States. The Company has plans to liquidate its Russian subsidiary. As such, the Company no longer asserts an intention to permanently re-invest those earnings. The undistributed earnings of the Company’s foreign subsidiaries were immaterial as of December 31, 2024 and 2023 and no U.S. income taxes have been accrued. A valuation allowance is provided for deferred tax assets where the recoverability of the assets is uncertain. The determination to provide a valuation allowance is dependent upon the assessment of whether it is more likely than not that sufficient future taxable income will be generated to utilize the deferred tax assets. Based on the weight of the available evidence, which includes the Company’s historical operating losses, lack of taxable income and the accumulated deficit for the year ended December 31, 2024, the Company has provided a valuation allowance against its U.S. net deferred tax assets. The Company has recorded net foreign deferred tax assets associated with its Australia, Germany, India, Portugal and the U.K. operations totaling $3.5 million since management has assessed it is more likely than not that the results of future operations within these jurisdictions will generate sufficient taxable income to realize the deferred tax assets. The foreign deferred tax assets cannot increase its U.S. valuation allowance. The net change in the valuation allowance for the years ended December 31, 2024 and 2023 were decreases of $11.7 million and $0.6 million, respectively. The decrease of the valuation allowance in the current year was primarily attributed to the Company’s acquisition of Acqueon, which provided a source of future U.S. taxable income to support a reduction in the consolidated U.S. valuation allowance. As of December 31, 2024, the Company had net operating loss carryforwards for federal, state and foreign income tax purposes of $310.1 million, $254.3 million and $7.3 million, respectively, available to reduce future income subject to income taxes. If not utilized, various amounts of significant state net operating loss carryforwards will begin to expire in 2028, while $310.1 million of federal net operating losses, as well as the foreign net operating losses, do not expire. As of December 31, 2024, the Company also had gross research credit carryforwards for federal and California state tax purposes of $14.1 million and $8.6 million, available to reduce future income subject to income taxes. The federal research credit carryforwards will expire between 2025 and 2044. The California state research credits do not expire. The IRC imposes restrictions on the utilization of net operating losses and credits in the event of an “ownership change” of a corporation. Accordingly, a company’s ability to use net operating losses and credits may be subject to substantial limitation as prescribed under the IRC Sections 382 and 383 and similar state provisions. Events that may cause limitations in the amount of the net operating losses and credits that the Company may use in any one year include, but are not limited to, a cumulative ownership change of more than 50% over a three-year period. In the event the Company has changes in ownership, net operating losses and research and development credit carryforwards, which are fully reserved by the deferred tax asset valuation allowance, could be limited and may expire unutilized. Unrecognized Tax Benefits The table below shows the changes in the gross amount of unrecognized tax benefits for the periods presented (in thousands):
|  | Year Ended December 31,
|  | 2024 |  | 2023 |  | 2022
Unrecognized benefit — beginning of period |  | $ | 11,124 |  |  | $ | 9,415 |  |  | $ | 7,643 |
Gross increases — current year tax positions |  | 2,502 |  |  | 1,413 |  |  | 1,773 |
Gross increases — prior year tax positions |  | 40 |  |  | 299 |  |  | — |
Gross decreases — prior year tax positions |  | (91) |  |  | (3) |  |  | (1) |
Settlements with tax authorities |  | — |  |  | — |  |  | — |
Unrecognized benefit — end of period |  | $ | 13,575 |  |  | $ | 11,124 |  |  | $ | 9,415 |
As of each of December 31, 2024 and 2023, the Company had unrecognized tax benefits that, if recognized, would impact its effective tax rate by $1.0 million and $0.5 million, respectively. The Company recognizes interest and penalties related to uncertain tax positions as income tax expense, which has cumulatively been immaterial to the financial statements. The Company does not anticipate its total unrecognized tax benefits as of December 31, 2024 will significantly change due to settlement of examination or the expiration of statutes of limitation during the next 12 months. The Company is currently unaware of any uncertain tax positions that could result in significant additional payments, accruals or other material deviation in this estimate over the next 12 months. The Company is subject to taxation in the United States, various states and several foreign jurisdictions. Due to the Company’s recently utilized and net carryover of unused operating losses, all years from 2004 forward remain subject to future examination by the U.S. federal and state tax authorities. The Company’s foreign tax returns are open to audit under the statutes of limitation of the respective foreign countries in which the subsidiaries are located. With the exception of Russia, the Company considers all undistributed earnings of its foreign subsidiaries indefinitely reinvested.

X
- References No definition available. + Details
Name: | us-gaap_IncomeTaxDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for income tax. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContent Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details
Name: | us-gaap_IncomeTaxDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration